At siRNAgen Therapeutics, we are dedicated to advancing the field of RNA interference (RNAi) to bring innovative and effective therapies to patients with chronic and intractable diseases. Our mission is to harness the power of RNA science to create medicines that make a meaningful difference in people’s lives.
Founded as a subsidiary of BIONEER Corporation, Korea’s first biotechnology company, siRNAgen builds on decades of scientific expertise and a global network in molecular diagnostics and life sciences. Our proprietary SAMiRNA® platform overcomes critical challenges in RNAi drug delivery and stability, enabling us to pursue next-generation therapeutics with precision and safety.
We are driven by a commitment to scientific excellence, collaboration, and patient-centered innovation. By working closely with partners and experts worldwide, we strive to deliver RNAi solutions that address unmet medical needs and improve health outcomes for patients globally.